Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly

Albert J. ten Tije, Jaap Verweij, Michael A Carducci, Wilfried Graveland, Theresa Rogers, Tatjana Pronk, M. P. Verbruggen, Fitzroy Dawkins, Sharyn D. Baker

Research output: Contribution to journalArticle

Abstract

Purpose: To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer. Patients and Methods: Docetaxel was administered at a dose 75 mg/m2 once every 3 weeks to 25 elderly cancer patients aged ≥ 65 years and 26 cancer patients aged younger than 65 years. Pharmacokinetic studies and toxicity assessments were performed during the first cycle of therapy. Results: Of 51 patients treated, 20 aged ≥ 65 years (median, 71 years; range, 65 to 80 years) and 20 aged younger than 65 years (median, 53 years; range, 26 to 64 years) were assessable for pharmacokinetic studies, and 39 were assessable for toxicity. Patient characteristics were similar (P ≥ .15) between the two cohorts. Mean docetaxel clearance was not altered in the elderly versus younger patients: 30.1 L/h (standard deviation [SD] 18.3 L/h) v 30.0 L/h (SD, 14.8 L/h; P = .98). The percentage of patients with grade 4 and febrile neutropenia was higher in the elderly (63% and 16%, respectively) versus younger (30% and 0%, respectively) cohort, although this observation did not reach a level of statistical significance (P = .056). From logistic regression analysis, the odds ratio for a patient aged 65 years was 1.98 for developing grade 4 neutropenia compared with a patient aged 50 years (P = .091). Conclusion: Docetaxel plasma pharmacokinetics are unaltered in elderly patients. Patients aged ≥ 65 years appear to be more sensitive to docetaxel-induced neutropenia.

Original languageEnglish (US)
Pages (from-to)1070-1077
Number of pages8
JournalJournal of Clinical Oncology
Volume23
Issue number6
DOIs
StatePublished - Feb 20 2005
Externally publishedYes

Fingerprint

docetaxel
Pharmacokinetics
Neutropenia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. / ten Tije, Albert J.; Verweij, Jaap; Carducci, Michael A; Graveland, Wilfried; Rogers, Theresa; Pronk, Tatjana; Verbruggen, M. P.; Dawkins, Fitzroy; Baker, Sharyn D.

In: Journal of Clinical Oncology, Vol. 23, No. 6, 20.02.2005, p. 1070-1077.

Research output: Contribution to journalArticle

ten Tije, AJ, Verweij, J, Carducci, MA, Graveland, W, Rogers, T, Pronk, T, Verbruggen, MP, Dawkins, F & Baker, SD 2005, 'Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly', Journal of Clinical Oncology, vol. 23, no. 6, pp. 1070-1077. https://doi.org/10.1200/JCO.2005.03.082
ten Tije, Albert J. ; Verweij, Jaap ; Carducci, Michael A ; Graveland, Wilfried ; Rogers, Theresa ; Pronk, Tatjana ; Verbruggen, M. P. ; Dawkins, Fitzroy ; Baker, Sharyn D. / Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 6. pp. 1070-1077.
@article{1fe1c8cfde9a433696f62c5b5a8063ca,
title = "Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly",
abstract = "Purpose: To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer. Patients and Methods: Docetaxel was administered at a dose 75 mg/m2 once every 3 weeks to 25 elderly cancer patients aged ≥ 65 years and 26 cancer patients aged younger than 65 years. Pharmacokinetic studies and toxicity assessments were performed during the first cycle of therapy. Results: Of 51 patients treated, 20 aged ≥ 65 years (median, 71 years; range, 65 to 80 years) and 20 aged younger than 65 years (median, 53 years; range, 26 to 64 years) were assessable for pharmacokinetic studies, and 39 were assessable for toxicity. Patient characteristics were similar (P ≥ .15) between the two cohorts. Mean docetaxel clearance was not altered in the elderly versus younger patients: 30.1 L/h (standard deviation [SD] 18.3 L/h) v 30.0 L/h (SD, 14.8 L/h; P = .98). The percentage of patients with grade 4 and febrile neutropenia was higher in the elderly (63{\%} and 16{\%}, respectively) versus younger (30{\%} and 0{\%}, respectively) cohort, although this observation did not reach a level of statistical significance (P = .056). From logistic regression analysis, the odds ratio for a patient aged 65 years was 1.98 for developing grade 4 neutropenia compared with a patient aged 50 years (P = .091). Conclusion: Docetaxel plasma pharmacokinetics are unaltered in elderly patients. Patients aged ≥ 65 years appear to be more sensitive to docetaxel-induced neutropenia.",
author = "{ten Tije}, {Albert J.} and Jaap Verweij and Carducci, {Michael A} and Wilfried Graveland and Theresa Rogers and Tatjana Pronk and Verbruggen, {M. P.} and Fitzroy Dawkins and Baker, {Sharyn D.}",
year = "2005",
month = "2",
day = "20",
doi = "10.1200/JCO.2005.03.082",
language = "English (US)",
volume = "23",
pages = "1070--1077",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly

AU - ten Tije, Albert J.

AU - Verweij, Jaap

AU - Carducci, Michael A

AU - Graveland, Wilfried

AU - Rogers, Theresa

AU - Pronk, Tatjana

AU - Verbruggen, M. P.

AU - Dawkins, Fitzroy

AU - Baker, Sharyn D.

PY - 2005/2/20

Y1 - 2005/2/20

N2 - Purpose: To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer. Patients and Methods: Docetaxel was administered at a dose 75 mg/m2 once every 3 weeks to 25 elderly cancer patients aged ≥ 65 years and 26 cancer patients aged younger than 65 years. Pharmacokinetic studies and toxicity assessments were performed during the first cycle of therapy. Results: Of 51 patients treated, 20 aged ≥ 65 years (median, 71 years; range, 65 to 80 years) and 20 aged younger than 65 years (median, 53 years; range, 26 to 64 years) were assessable for pharmacokinetic studies, and 39 were assessable for toxicity. Patient characteristics were similar (P ≥ .15) between the two cohorts. Mean docetaxel clearance was not altered in the elderly versus younger patients: 30.1 L/h (standard deviation [SD] 18.3 L/h) v 30.0 L/h (SD, 14.8 L/h; P = .98). The percentage of patients with grade 4 and febrile neutropenia was higher in the elderly (63% and 16%, respectively) versus younger (30% and 0%, respectively) cohort, although this observation did not reach a level of statistical significance (P = .056). From logistic regression analysis, the odds ratio for a patient aged 65 years was 1.98 for developing grade 4 neutropenia compared with a patient aged 50 years (P = .091). Conclusion: Docetaxel plasma pharmacokinetics are unaltered in elderly patients. Patients aged ≥ 65 years appear to be more sensitive to docetaxel-induced neutropenia.

AB - Purpose: To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer. Patients and Methods: Docetaxel was administered at a dose 75 mg/m2 once every 3 weeks to 25 elderly cancer patients aged ≥ 65 years and 26 cancer patients aged younger than 65 years. Pharmacokinetic studies and toxicity assessments were performed during the first cycle of therapy. Results: Of 51 patients treated, 20 aged ≥ 65 years (median, 71 years; range, 65 to 80 years) and 20 aged younger than 65 years (median, 53 years; range, 26 to 64 years) were assessable for pharmacokinetic studies, and 39 were assessable for toxicity. Patient characteristics were similar (P ≥ .15) between the two cohorts. Mean docetaxel clearance was not altered in the elderly versus younger patients: 30.1 L/h (standard deviation [SD] 18.3 L/h) v 30.0 L/h (SD, 14.8 L/h; P = .98). The percentage of patients with grade 4 and febrile neutropenia was higher in the elderly (63% and 16%, respectively) versus younger (30% and 0%, respectively) cohort, although this observation did not reach a level of statistical significance (P = .056). From logistic regression analysis, the odds ratio for a patient aged 65 years was 1.98 for developing grade 4 neutropenia compared with a patient aged 50 years (P = .091). Conclusion: Docetaxel plasma pharmacokinetics are unaltered in elderly patients. Patients aged ≥ 65 years appear to be more sensitive to docetaxel-induced neutropenia.

UR - http://www.scopus.com/inward/record.url?scp=14544297866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544297866&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.082

DO - 10.1200/JCO.2005.03.082

M3 - Article

VL - 23

SP - 1070

EP - 1077

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -